Edition:
United States

Enanta Pharmaceuticals Inc (ENTA.OQ)

ENTA.OQ on NASDAQ Stock Exchange Global Select Market

31.31USD
25 Apr 2017
Change (% chg)

-- (--)
Prev Close
$31.31
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
80,180
52-wk High
$37.24
52-wk Low
$20.92

Latest Key Developments (Source: Significant Developments)

Abbvie granted priority review in Japan for its investigational regimen of Glecaprevir
Tuesday, 14 Mar 2017 08:00am EDT 

Abbvie Inc : Abbvie granted priority review in Japan for its investigational regimen of Glecaprevir/Pibrentasvir (G/P) for the treatment of all major genotypes of chronic hepatitis c .Priority review follows EMA accelerated assessment and U.S. FDA priority review designations in December 2016 and January 2017 respectively.  Full Article

Enanta says CHMP gives positive opinion for AbbVie's hep C treatment for patients with genotype 1B
Monday, 27 Feb 2017 06:00am EST 

Enanta Pharmaceuticals Inc : Enanta announces CHMP grants positive opinion for an eight-week treatment option with Abbvie's Viekirax® (ombitasvir/paritaprevir/ritonavir tablets) + exviera® (dasabuvir tablets) for patients with genotype 1b chronic hepatitis c . Says Abbvie's EMA label expansion is supported by 98 percent svr 12 rate in patients in dedicated phase 3b garnet study .Says chmp positive opinion is supported by data from dedicated phase 3b garnet study.  Full Article

Enanta Pharmaceuticals Q1 loss per share $0.26
Wednesday, 8 Feb 2017 04:02pm EST 

Enanta Pharmaceuticals Inc : Enanta Pharmaceuticals reports financial results for its fiscal first quarter ended december 31, 2016 . Q1 loss per share $0.26 . Q1 revenue $10.4 million versus I/B/E/S view $11.9 million . Q1 earnings per share view $-0.18 -- Thomson Reuters I/B/E/S . Enanta Pharmaceuticals Inc - expect to complete phase 1 study of edp-305 mid-year and later this year plan to initiate a phase 2 study of edp-305 in pbc . Enanta -expect to complete phase 1 study of edp-305 mid-year and later this year plan to initiate a phase 2 study of edp-305 in pbc .Enanta Pharmaceuticals Inc says also plan initiation of clinical development of our lead rsv compound, edp-938 in calendar 2017.  Full Article

FDA grants fast track designation to Enanta's FXR Agonist candidate, EDP-305
Wednesday, 4 Jan 2017 07:30am EST 

Enanta Pharmaceuticals Inc :FDA grants fast track designation to Enanta's FXR Agonist candidate, EDP-305, for the treatment of nash with liver fibrosis.  Full Article

Enanta Pharmaceuticals reports financial results for its fiscal fourth quarter and year ended September 30, 2016
Monday, 21 Nov 2016 04:01pm EST 

Enanta Pharmaceuticals Inc : Enanta Pharmaceuticals reports financial results for its fiscal fourth quarter and year ended September 30, 2016 . Q4 earnings per share view $-0.14 -- Thomson Reuters I/B/E/S .Q4 loss per share $0.09.  Full Article

Enanta Pharmaceuticals announces AbbVie's investigational HCV regimen receives U.S. FDA breakthrough therapy designation
Friday, 30 Sep 2016 08:00am EDT 

Enanta Pharmaceuticals Inc : Enanta Pharmaceuticals announces AbbVie's investigational HCV regimen receives U.S. FDA breakthrough therapy designation .According to FDA,BTD is intended to expedite development,review of an investigational therapy for serious condition.  Full Article

Enanta Pharmaceuticals Q3 loss per share $0.06
Monday, 8 Aug 2016 04:01pm EDT 

Enanta Pharmaceuticals Inc : Enanta Pharmaceuticals reports financial results for its fiscal third quarter ended June 30, 2016 . Q3 loss per share $0.06 . Q3 earnings per share view $-0.10 -- Thomson Reuters I/B/E/S . Q3 revenue $14 million versus I/B/E/S view $13 million .U.S. FDA granted marketing approval for Abbvie's Viekira XR((TM))for treatment of genotype 1 hepatitis c virus.  Full Article

Abbvie says CHMP grants positive opinion for shorter treatment duration with VIEKIRAX
Monday, 25 Jul 2016 04:00am EDT 

Abbvie Inc : CHMP grants positive opinion for shorter treatment duration with Abbvie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) for patients with genotype 4 chronic hepatitis C with compensated cirrhosis (child-pugh a) .Says VIEKIRAX with RBV is currently approved in European Union for GT4 patients with compensated cirrhosis for 24 weeks.  Full Article

Enanta pharmaceuticals Q2 loss per share $0.09
Monday, 9 May 2016 04:02pm EDT 

Enanta Pharmaceuticals Inc : Enanta pharmaceuticals reports financial results for its fiscal second quarter ended march 31, 2016 . Q2 loss per share $0.09 . Q2 earnings per share view $0.10 -- Thomson Reuters I/B/E/S . Q2 revenue $13 million versus $57.4 million .Q2 revenue view $16.8 million -- Thomson Reuters I/B/E/S.  Full Article

Enanta Pharmaceuticals Inc Announces Approval of VIEKIRAX(ombitasvir/paritaprevir/ritonavir tablets) in Japan for the Treatment of Genotype 1 Chronic Hepatitis C
Monday, 28 Sep 2015 06:00am EDT 

Enanta Pharmaceuticals Inc:Announces approval of viekirax®(ombitasvir/paritaprevir/ritonavir tablets) in Japan for the treatment of genotype 1 chronic hepatitis c.Says Japanese ministry of health, labour and welfare (mhlw) approved abbvie's viekirax.Expects to earn and receive a $30 million milestone payment in quarter ending December 31, 2015 upon price reimbursement approval of viekirax in Japan.45 percent of abbvie's net sales of the 2-daa regimen in Japan will be included in the worldwide paritaprevir net sales.AbbVie responsible for worldwide development,commercialization of viekirax,other hcv treatment regimens containing paritaprevir.Enanta is eligible to receive annually tiered royalties, ranging from the low double digits up to twenty percent.  Full Article

More From Around the Web

BRIEF-Enanta announces eight weeks of treatment with Abbvie's investigational drug achieved high SVR rates in challenging-to-treat genotype 3 chronic HCV patients

* Enanta announces eight weeks of treatment with Abbvie's investigational, pan-genotypic, ribavirin-free HCV regimen of glecaprevir/pibrentasvir (g/p) achieved high SVR rates in challenging-to-treat genotype 3 chronic HCV patients